Comparative Pharmacology
Head-to-head clinical analysis: ASCLERA versus OPSYNVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASCLERA versus OPSYNVI.
ASCLERA vs OPSYNVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASCLERA (corticotropin) is a proopiomelanocortin (POMC) analog that stimulates the adrenal cortex to release cortisol, corticosterone, and aldosterone, increasing corticosteroid levels. It also has immunomodulatory and anti-inflammatory effects mediated through melanocortin receptors.
OPSYNVI is a dual endothelin receptor antagonist (ERA) and phosphodiesterase-5 (PDE5) inhibitor. Macitentan blocks endothelin-1 (ET-1) receptors (ETA and ETB), reducing vasoconstriction and proliferation. Tadalafil inhibits PDE5, increasing cGMP levels and causing vasodilation.
Adults: 240 mg/m2 intravenously over 2 hours on day 1 of each 21-day cycle.
10 mg orally once daily, in combination with tadalafil 20 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours. In patients with moderate-to-severe renal impairment (CrCl < 30 mL/min), half-life may increase to 30-40 hours, requiring dose adjustment.
Terminal elimination half-life approximately 15 hours (range 10–20 hours) in patients with pulmonary arterial hypertension; supports twice-daily dosing.
Renal excretion of unchanged drug accounts for 60-70% of administered dose; fecal/biliary elimination contributes 20-30%.
Primarily fecal (approximately 66% of absorbed dose) and renal (approximately 22% as unchanged drug and metabolites). Biliary excretion is negligible.
Category C
Category C
Endothelin Receptor Antagonist
Endothelin Receptor Antagonist/Phosphodiesterase-5 Inhibitor Combination (PAH)